10-Q: SafeSpace Global Reports Widening Losses, Going Concern Doubt
Quarterly Report
SafeSpace Global Corporation's latest 10-Q filing reveals increased net losses and cash burn, raising substantial doubt about its ability to continue as a going concern, despite strategic partnerships.
Summary
- Reported a net loss of $2,741,987 for the six months ended January 31, 2026, compared to $1,950,574 for the same period in the prior year.
- Operating expenses significantly increased to $2,851,117 for the six months ended January 31, 2026, from $1,918,937 in the prior year.
- Cash and cash equivalents decreased to $3,861,070 as of January 31, 2026, from $7,546,390 as of July 31, 2025.
- Working capital decreased to $3,639,432 as of January 31, 2026, from $7,274,432 as of July 31, 2025.
- The company has not generated revenue in either the current or prior comparable periods.
- Management expressed substantial doubt about the company's ability to continue as a going concern.
- Disclosure controls and procedures were deemed ineffective due to material weaknesses in internal control over financial reporting.
Sentiment
Score: 2
Explanation: StockSavvy.ai views this filing as highly negative due to widening losses, significant cash burn, a stated going concern risk, and ineffective internal controls, overshadowing any operational progress.
Positives
- Renewed and broadened partnership with Signature HealthCARE to scale its multimodal AI safety platform across its communities.
- Secured a new partnership with Wayman Place (Longwood, FL) to implement its non-wearable elopement detection solution.
- Strengthened the development team with senior IT architects, AI specialists, and systems engineers.
- Increased interest income to $109,130 for the six months ended January 31, 2026, from $0 in the prior year.
- Paid off all outstanding debt, resulting in zero interest expense for the current six-month period.
- No intangible asset impairment charges recorded during the six months ended January 31, 2026, compared to $46,225 in the prior year.
- Significant increase in intangible assets, net to $1,259,075 as of January 31, 2026, from $290,469 as of July 31, 2025, indicating investment in development.
Negatives
- Reported a net loss of $2,741,987 for the six months ended January 31, 2026, a 40.6% increase from $1,950,574 in the prior year.
- Operating expenses increased by 48.6% to $2,851,117 for the six months ended January 31, 2026, from $1,918,937 in the prior year.
- Selling, general and administrative expenses increased by 187% to $2,336,872 for the six months ended January 31, 2026.
- Cash and cash equivalents decreased by 48.8% to $3,861,070 as of January 31, 2026, from $7,546,390 as of July 31, 2025.
- Working capital decreased by 49.9% to $3,639,432 as of January 31, 2026, from $7,274,432 as of July 31, 2025.
- Net cash used in operating activities increased by 180.2% to $2,446,642 for the six months ended January 31, 2026.
- The company has not generated any revenue in the current or prior comparable periods.
- Management identified substantial doubt about the company's ability to continue as a going concern.
- Disclosure controls and procedures were deemed ineffective due to material weaknesses in internal control over financial reporting.
Risks
- Ability to maintain and secure adequate capital to fund operations and fully develop products.
- Ability to source strong opportunities with sufficient risk-adjusted returns.
- Acceptance of the terms and conditions of licenses and/or the acceptance of royalties and fees.
- Nature and extent of competition from other companies that may reduce market share and create pressure on pricing and investment return expectations.
- Changes in the projects in which the company plans to invest, resulting from factors beyond its control, including changes in circumstances, capacity, and economic impacts.
- Changes in laws, regulations, accounting, taxation, and other requirements affecting operations and business.
- Inability to commercialize new products.
- Inability to hire and retain key personnel.
- Inability to secure sufficient funding to execute the growth plan.
- Patents may not prevent all competitors from developing similar products.
- Failure to comply with the Family Educational Rights and Privacy Act (FERPA) could limit or delay the ability to deploy SafeSchool in certain jurisdictions, impact customer adoption, or expose the company to regulatory risk.
- Material weaknesses in the design or operation of internal controls over financial reporting.
Future Outlook
The company aims to expand the adoption of its multimodal AI technology across existing and emerging verticals including senior living, education, transportation, and corrections, with future plans for commercial infrastructure and high-risk institutional settings. Management believes its current cash position of approximately $2,900,000 from recent private placements adequately supports its five-year strategic plan, enabling acquisitions, investments in advanced AI technology, and expansion of its technology development team.
Management Comments
- "Our primary objective is to expand the adoption of our life-saving multimodal AI technology across both existing and emerging verticals."
- "To support this growth, we have strengthened our development team with senior IT architects, AI specialists, and systems engineers who are accelerating product innovation and market deployment on a global scale."
- "Management believes this [approximately $2,900,000 in cash] adequately supports the Company's five-year strategic plan enabling strategic initiatives, such as acquisitions, investments in advanced AI technology, and the expansion of its technology development team."
- "SafeSpace Global Corporation remains committed to driving innovation in healthcare technology, with a focus on solutions that enhance safety, efficiency, and patient outcomes across various care settings."
- "It is management's opinion that these conditions [history of losses, accumulated deficit, no cash from operations] raise substantial doubt about the Company's ability to continue as a going concern."
Industry Context
StockSavvy.ai notes that SafeSpace Global operates in the rapidly evolving AI technology sector, specifically targeting safety innovation across multiple industries. While the company is securing partnerships in senior living, its lack of revenue generation and significant cash burn contrast sharply with the high growth and investment typically seen in successful AI ventures. The focus on multimodal AI and expansion into diverse verticals like education and corrections aligns with broader industry trends of applying AI to real-world safety challenges, but financial performance indicates a struggle to monetize these innovations effectively compared to more established or better-funded competitors.
Comparison to Industry Standards
- The absence of revenue generation for an AI technology company, especially one with significant operating expenses and investments in development, is a notable deviation from industry standards where successful tech companies typically demonstrate early revenue traction or clear pathways to monetization.
- The substantial increase in net loss and cash used in operating activities, coupled with a "going concern" warning, places the company significantly below the financial health benchmarks for publicly traded technology firms, which are expected to show progress towards profitability or sustainable growth.
- The reported ineffectiveness of disclosure controls and procedures is a serious corporate governance issue, falling short of the robust internal control standards expected of public companies, particularly those in the technology sector handling sensitive data.
- While investment in intangible assets and property/equipment indicates R&D efforts, the lack of corresponding revenue or clear path to profitability suggests these investments are not yet yielding competitive returns, unlike many peers who demonstrate a clearer ROI on technology development.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer and Chairman of the Board of Directors | Scott M. Boruff (via Platinum Equity Advisors, LLC) at $240,000 annually | Scott M. Boruff (via Platinum Equity Advisors, LLC) at $315,000 annually | 2025-10-01 | Annual compensation increase. |
| Chief Medical Officer | Susan A. Reyes, MD at $24,000 per annum | Susan A. Reyes, MD at up to $92,000 per annum | 2023-08-01 | Potential increase in base salary at CEO's discretion to reflect increased time commitment. |
| President & Chief Strategy Officer | Dustin M. Hillis (via All Things New Ventures, LLC) at $100,000 annually | Dustin M. Hillis (via All Things New Ventures, LLC) at $150,000 annually | 2025-04-01 | Annual base fee increase via First Amendment. |
| President & Chief Strategy Officer | Dustin M. Hillis (via All Things New Ventures, LLC) at $150,000 annually | Dustin M. Hillis (via All Things New Ventures, LLC) at $225,000 annually | 2025-10-01 | Annual compensation increase. |
| Chief Technology Officer | NA | Anand Ijju | 2025-05-01 | Appointment to new role, with an annual salary of $150,000 and a stock grant of 500,000 shares. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure Controls and Procedures | Management concluded that disclosure controls and procedures were not effective in providing reasonable assurances that required information was recorded, processed, summarized, and reported within prescribed time periods. | 2026-01-31 | Indicates material weaknesses in internal control over financial reporting, potentially affecting the reliability and timeliness of financial disclosures. |
Legal Proceedings
- None.
Related Party Transactions
- Platinum Equity Advisors, LLC (owned by the spouse of the CEO and Chairman of the Board) provides CEO services. The company owed Platinum Equity $0 as of January 31, 2026, down from $5,492 as of July 31, 2025.
- Related parties were owed $0 as of January 31, 2026, down from $2,339 as of July 31, 2025, for temporary loans primarily related to vendor payments, payable on demand with no interest.
Stakeholder Impact
- Shareholders: Face significant dilution risk from potential future equity raises, substantial losses, and the going concern warning. The ineffectiveness of disclosure controls also poses a risk to investor confidence.
- Employees: Benefit from stock-based compensation and increased salaries for key executives, but the company's going concern status introduces job security uncertainty.
- Customers: Existing partnerships (Signature HealthCARE, Wayman Place) suggest continued product deployment and support, but the company's financial instability could raise concerns about long-term viability and service continuity.
- Creditors: Current liabilities are decreasing, and related party debt is paid off, which is positive, but the overall financial health and going concern risk could impact future credit availability and terms.
- Suppliers: Accounts payable decreased, which is positive for suppliers, but the company's financial position could lead to tighter payment terms or scrutiny from new suppliers.
Next Steps
- Continue marketing and sales of products to achieve profitability.
- Finance future development activities and working capital needs from the sale of private and public equity securities, with possible additional funding from other traditional financing sources.
- Expand adoption of multimodal AI technology across senior living, education, transportation, and corrections.
- Future expansion planned into commercial infrastructure and high-risk institutional settings.
- Recognize all outstanding contract liabilities over the next 12 months.
- Evaluate the effect of adopting ASU 2024-03 (effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027).
- Assess the impact of ASU 2023-09 on income tax disclosures and related cash flow disclosures (effective for annual periods beginning after December 15, 2024).
- Commence new office lease agreement on August 1, 2026, expiring April 30, 2032.
Key Dates
| Date | Description |
|---|---|
| 2020-10-19 | Grant date for a restricted stock award to a consultant. |
| 2023-08-01 | Effective date for the Non-Employee Chief Executive Officer Engagement Agreement with Platinum Equity Advisors, LLC, and Dr. Reyes' employment agreement. |
| 2023-09-01 | Grant date for a restricted stock award to a consultant. |
| 2024-01-31 | Date of entry into the Non-Employee Chief Executive Officer Engagement Agreement with Platinum Equity Advisors, LLC, and Dr. Reyes' employment agreement. |
| 2024-07-31 | Fiscal year end for the prior period. |
| 2024-08-01 | Effective date for the CEO's base fee increase to $240,000 annually. Grant date for a restricted stock award to a consultant. |
| 2024-10-19 | Grant date for a restricted stock award to a consultant. |
| 2024-10-24 | Grant date for a restricted stock award to a consultant. |
| 2024-10-29 | Date Annual Report on Form 10-K for the year ended July 31, 2025, was filed with the SEC. |
| 2024-11-01 | Grant date for a restricted stock award to a consultant. |
| 2024-11-15 | Grant date for a restricted stock award to a consultant. |
| 2024-12-02 | Grant date for restricted stock awards to consultants. |
| 2024-12-04 | Grant date for a restricted stock award to a consultant. |
| 2024-12-15 | Grant date for a restricted stock award to a consultant. |
| 2024-12-31 | Effective date for ASU 2023-09 for public business entities for annual periods beginning after this date. |
| 2025-01-01 | Date of entry into the Non-Employee President & Chief Strategy Officer Engagement Agreement with All Things New Ventures, LLC. |
| 2025-01-02 | Grant date for a restricted stock award to a consultant. |
| 2025-01-06 | Grant date for a restricted stock award to a consultant. |
| 2025-01-13 | Grant date for a restricted stock award to a consultant. |
| 2025-01-20 | Grant date for a restricted stock award to an employee. |
| 2025-01-29 | Date the CEO agreement was updated, entitling the executive to a 5% override on sales. |
| 2025-01-31 | End of the six-month reporting period for the prior year. |
| 2025-03-17 | Grant date for a restricted stock award to a consultant. |
| 2025-03-24 | Grant date for a restricted stock award to a consultant. |
| 2025-04-01 | Effective date of the First Amendment to Mr. Hillis's agreement, increasing annual base fee to $150,000. |
| 2025-04-10 | Date Mr. Anand Ijju was appointed as Chief Technology Officer. |
| 2025-05-01 | Mr. Ijju's employment with the Company began. First vesting date for Mr. Ijju's stock grant. |
| 2025-07-31 | Fiscal year end for the current period. Balance sheet date for prior fiscal year. |
| 2025-08-01 | Issuance of 100,000 unregistered shares to a consultant (vesting from 2024-08-01 award). Issuance of 250,000 unregistered shares to a consultant (vesting from 2025-08-01 award). Issuance of 250,000 unregistered shares to a consultant (vesting from 2025-08-01 award). |
| 2025-08-25 | Issuance of 333,334 unregistered shares to a Board member as compensation. |
| 2025-08-31 | Issuance of 200,000 unregistered shares to a consultant (vesting from 2023-09-01 award). |
| 2025-09-19 | Issuance of 100,000 unregistered shares to a consultant (vesting from 2025-08-01 award). |
| 2025-09-24 | Issuance of 30,000 unregistered shares to a consultant (vesting from 2025-03-24 award). |
| 2025-10-01 | Annual compensation for CEO increased to $315,000. Annual compensation for President & Chief Strategy Officer increased to $225,000. |
| 2025-10-19 | Issuance of 250,000 unregistered shares to a consultant (vesting from 2020-10-19 award). |
| 2025-10-24 | Issuance of 500,000 unregistered shares to a consultant (vesting from 2024-10-24 award). |
| 2025-11-01 | Grant date for restricted stock awards to consultants and an employee. |
| 2025-11-15 | Issuance of 29,041 unregistered shares to a consultant (vesting from 2024-08-01 award). Issuance of 83,836 unregistered shares to a consultant (vesting from 2025-01-13 award). Issuance of 100,000 unregistered shares to a consultant (vesting from 2024-11-15 award). |
| 2025-12-01 | Issuance of 100,000 unregistered shares to a consultant (vesting from 2024-12-02 award). |
| 2025-12-02 | Issuance of 100,000 unregistered shares to a consultant (vesting from 2024-12-02 award). |
| 2025-12-04 | Issuance of 100,000 unregistered shares to a consultant (vesting from 2024-12-04 award). |
| 2025-12-15 | Issuance of 316,895 unregistered shares to a consultant (vesting from 2025-01-02 award). |
| 2026-01-01 | Issuance of 250,000 unregistered shares to a consultant (vesting from 2025-11-01 award). Issuance of 250,000 unregistered shares to a consultant (vesting from 2025-11-01 award). |
| 2026-01-02 | Issuance of 100,000 unregistered shares to an employee (vesting from 2025-11-01 award). |
| 2026-01-05 | Issuance of 100,000 unregistered shares to a consultant (vesting from 2024-12-02 award). |
| 2026-01-08 | Issuance of 100,000 unregistered shares to a consultant (vesting from 2025-01-06 award). Issuance of 74,795 unregistered shares to a consultant (vesting from 2025-03-17 award). |
| 2026-01-20 | Issuance of 100,000 unregistered shares to an employee (vesting from 2025-01-20 award). |
| 2026-01-31 | End of the current six-month reporting period. |
| 2026-02-26 | Date the company entered into a new noncancelable operating lease agreement for office space. |
| 2026-03-12 | Date as of which 189,429,097 shares of common stock were outstanding. |
| 2026-03-17 | Date the report was signed by the CEO and Principal Accounting Officer. |
| 2026-08-01 | Commencement date for the new office lease agreement. |
| 2026-12-15 | Effective date for ASU 2024-03 for annual reporting periods for public entities. |
| 2027-12-15 | Effective date for ASU 2024-03 for interim reporting periods for public entities. |
| 2032-04-30 | Expiration date for the new office lease agreement. |
Recommendation
strong sellThe company's financial performance is severely deteriorating, marked by widening net losses, a substantial increase in cash used for operations, and a significant decline in cash reserves. The explicit 'going concern' warning, coupled with the complete absence of revenue and ineffective disclosure controls, indicates profound operational and financial instability. While strategic partnerships are noted, they have not translated into revenue or reduced losses. These factors present an extremely high risk profile for investors, warranting a strong sell recommendation.
Keywords
AI technology, safety innovation, multimodal AI, senior living, education technology, healthcare technology, resident safety, elopement detection, corporate governance, SEC filing, 10-Q, financial reporting, going concern, software development, risk management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.